Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSB | P07858 | 2/20 | 0.45 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.45 |
| ▸ | RXRA | P19793 | 1/20 | 0.41 |
| ▸ | RXRB | P28702 | 1/20 | 0.41 |
| ▸ | RXRG | P48443 | 1/20 | 0.41 |
| ▸ | AOC2 | O75106 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 8/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | APEX1 | P27695 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 4/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8763089 | 0.81 | ESR2 (0.42) | ALDH1A1MEN1KMT2AESR1ESR2 | |
| SCHEMBL8245249 | 0.80 | CTSB (0.52) | CTSBKLKB1RXRARXRBRXRG | |
| SCHEMBL26936224 | 0.77 | ACACB (0.40) | ALDH1A1MEN1KMT2ATDP1ESR1 | |
| SCHEMBL9672981 | 0.77 | ACACB (0.40) | ALDH1A1MEN1KMT2ATDP1ESR1 | |
| SCHEMBL4397469 | 0.74 | CTSB (0.50) | CTSBKLKB1RXRARXRBRXRG | |
| SCHEMBL5877976 | 0.73 | ALDH1A1 (0.42) | CTSBKLKB1RXRARXRBRXRG | |
| SCHEMBL7717085 | 0.72 | ESR2 (0.36) | ALDH1A1MEN1KMT2AESR1ESR2 | |
| SCHEMBL3945082 | 0.72 | CYP2A6 (0.54) | ALDH1A1HSD17B10 | |
| SCHEMBL13643237 | 0.72 | ACACB (0.41) | ALDH1A1MEN1KMT2AMAPK1L3MBTL1 | |
| SCHEMBL7011495 | 0.72 | ESR1 (0.58) | ALDH1A1MEN1KMT2AESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7135487-B2 | such as N-2-(4-Bromophenyl)propyl methanesulfonamide; sulfonamidation of the amine; glutamate receptor potentiators | ELI LILLY AND COMPANY (US) | 2006-11-14 | — | — | US | disclosed |
| US-20060030599-A1 | SULPHONAMIDE DERIVATIVES | ARNOLD MACKLIN B | 2006-02-09 | — | — | US | disclosed |
| EP-1528055-A2 | Sulphonamide Derivatives | Eli Lilly & Company (US) | 2005-05-04 | — | — | EP | disclosed |
| EP-0860428-B1 | Sulphonamide derivatives | LILLY CO ELI (US) | 2004-12-08 | — | — | EP | disclosed |
| US-20040097499-A1 | Amide, carbamate, and urea derivatives | ARNOLD MACKLIN BRIAN (US) | 2004-05-20 | — | — | US | disclosed |
| US-20040054009-A1 | (BIS)sulfonamide derivatives | KNOBELSDORF JAMES ALLEN (US) | 2004-03-18 | — | — | US | disclosed |
| US-6617351-B1 | Amide, carbamate, and urea derivatives | ELI LILLY AND COMPANY | 2003-09-09 | — | — | US | disclosed |
| US-6596716-B2 | 2-propane-sulphonamide derivatives | ELI LILLY AND COMPANY | 2003-07-22 | — | — | US | disclosed |
| US-6525099-B1 | Potentiating glutamate receptor function; psychiatric and neurological disorders | ELI LILLY AND COMPANY | 2003-02-25 | — | — | US | disclosed |
| US-6521605-B1 | Potentiating glutamate receptor function; treating such as psychiatric and neurological disorders | ELI LILLY AND COMPANY | 2003-02-18 | — | — | US | disclosed |
| US-20020002158-A1 | Sulphonamide derivatives | ARNOLD MACKLIN B (US) | 2002-01-03 | — | — | US | disclosed |
| US-6303816-B1 | Sulphonamide derivatives | ELI LILLY AND COMPANY | 2001-10-16 | — | — | US | disclosed |
| WO-2000006537-A1 | N-SUBSTITUTED SULFONAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2000-02-10 | — | — | WO | disclosed |
| EP-0976744-A1 | Amide, carbamate, and urea derivatives having glutamate receptor function potentiating activity | ELI LILLY AND COMPANY (US) | 2000-02-02 | — | — | EP | disclosed |
| EP-0860428-A2 | Sulphonamide derivatives | ELI LILLY AND COMPANY (US) | 1998-08-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060030599-A1 | SULPHONAMIDE DERIVATIVES | GRIN2C, GLRA2, GLRA1 | CTSB 2192/4885KLKB1 4705/4885RXRA 1427/4885 |
| US-20020002158-A1 | Sulphonamide derivatives | GRIN2C, GRM1, GRM3 | CTSB 3296/4885KLKB1 4669/4885RXRA 1052/4885 |
| US-20040054009-A1 | (BIS)sulfonamide derivatives | GRIN2A, GRIN2B, GABRE | CTSB 2437/4885KLKB1 4256/4885RXRA 1186/4885 |
| US-20040097499-A1 | Amide, carbamate, and urea derivatives | GRIN2A, GLUL, GRIK5 | CTSB 1153/4885KLKB1 4266/4885RXRA 441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.